Hospira Recalls Hydromorphone Hydrochloride Injection Due to Silicone Oil Particulates
Hospira is recalling 56,340 vials of Hydromorphone Hydrochloride Injection because of the presence of silicone oil particulate matter.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or hospitalizations, fitting the criteria for a moderate severity precautionary recall.
Plain-English summary
Hospira Inc. is recalling 56,340 vials of Hydromorphone Hydrochloride Injection, USP, 50 mg/5 mL (10 mg/mL). The product is distributed in 5 mL single-dose vials, packaged as 10 vials per carton (NDC 0703-0113-01) and 180 vials per case (NDC 0703-0113-03). The specific lot affected is 560103F, with an expiration date of 01AUG2017.
The recall was initiated due to the presence of particulate matter, specifically silicone oil, in the injection. The product was manufactured by Hospira, Inc., in Lake Forest, IL, for Teva Parenteral Medicines, Inc., in Irvine, CA. The affected units were distributed nationwide in the USA.
Healthcare providers and patients should discontinue use of the affected lot and return the product to the distributor or manufacturer. Consumers should check their medication for the specific lot number and expiration date listed above to determine if they are affected.
The recalled product
- Product
- HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE)
- Brand
- HYDROMORPHONE HYDROCHLORIDE
- Manufacturer
- HOSPIRA INC, LAKE FOREST
- Category
- Drug — Injectable
- Affected units
- 56,340
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 560103F
- Exp. 01AUG2017
UPCs (1)
- 0307030110038
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by HOSPIRA INC, LAKE FOREST under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · HYDROMORPHONE HYDROCHLORIDE
- SeverePfizer Recalls Hydromorphone Hydrochloride Injection Vials Due to Non-Sterility
FDA (Drugs) · 2018-03-21
- CriticalPfizer Recalls Hydromorphone Hydrochloride Injection Due to Non-Sterility Concerns
FDA (Drugs) · 2018-03-21
- SeverePfizer Recalls Hydromorphone Hydrochloride Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2017-09-27
- ModerateHospira Recalls Hydromorphone Hydrochloride Injection Due to Silicone Oil Particulates
FDA (Drugs) · 2017-08-16
- SevereHospira Recalls Hydromorphone Hydrochloride Injection Due to Silicone Oil Particulates
FDA (Drugs) · 2017-08-16
Same manufacturer · HOSPIRA INC, LAKE FOREST
See all →- SevereHospira Recalls Naloxone Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2018-06-13
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26